180 related articles for article (PubMed ID: 15225711)
1. Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
Buzzoni V; Blazquez J; Ferrari S; Calò S; Venturelli A; Costi MP
Bioorg Med Chem Lett; 2004 Aug; 14(15):3979-83. PubMed ID: 15225711
[TBL] [Abstract][Full Text] [Related]
2. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
Weston GS; Blázquez J; Baquero F; Shoichet BK
J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
[TBL] [Abstract][Full Text] [Related]
3. Activity of mecillinam against AmpC beta-lactamase-producing Escherichia coli.
Brenwald NP; Andrews J; Fraise AP
J Antimicrob Chemother; 2006 Jul; 58(1):223-4. PubMed ID: 16698846
[No Abstract] [Full Text] [Related]
4. Diagnostic utility of boronic acid inhibition with different cephalosporins against Escherichia coli producing AmpC β-lactamases.
Upadhyay S; Sen MR; Bhattacharjee A
J Med Microbiol; 2011 May; 60(Pt 5):691-3. PubMed ID: 21292860
[No Abstract] [Full Text] [Related]
5. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.
Coudron PE
J Clin Microbiol; 2005 Aug; 43(8):4163-7. PubMed ID: 16081966
[TBL] [Abstract][Full Text] [Related]
6. Disc methods for detecting AmpC {beta}-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae.
Brenwald NP; Jevons G; Andrews J; Ang L; Fraise AP
J Antimicrob Chemother; 2005 Sep; 56(3):600-1. PubMed ID: 16087656
[No Abstract] [Full Text] [Related]
7. Nanomolar inhibitors of AmpC beta-lactamase.
Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F
J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668
[TBL] [Abstract][Full Text] [Related]
8. Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli.
Song W; Bae IK; Lee YN; Lee CH; Lee SH; Jeong SH
J Clin Microbiol; 2007 Apr; 45(4):1180-4. PubMed ID: 17301276
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.
Usher KC; Blaszczak LC; Weston GS; Shoichet BK; Remington SJ
Biochemistry; 1998 Nov; 37(46):16082-92. PubMed ID: 9819201
[TBL] [Abstract][Full Text] [Related]
10. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
Tan TY; Ng SY; Teo L; Koh Y; Teok CH
J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic detection of extended-spectrum and AmpC beta-lactamases by a new spot-inoculation method and modified three-dimensional extract test: comparison with the conventional three-dimensional extract test.
Shahid M; Malik A; Agrawal M; Singhal S
J Antimicrob Chemother; 2004 Sep; 54(3):684-7. PubMed ID: 15294886
[TBL] [Abstract][Full Text] [Related]
12. Interplay of efflux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli.
Källman O; Giske CG; Samuelsen Ø; Wretlind B; Kalin M; Olsson-Liljequist B
Microb Drug Resist; 2009 Jun; 15(2):91-5. PubMed ID: 19432520
[TBL] [Abstract][Full Text] [Related]
13. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
14. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.
Venturelli A; Tondi D; Cancian L; Morandi F; Cannazza G; Segatore B; Prati F; Amicosante G; Shoichet BK; Costi MP
J Med Chem; 2007 Nov; 50(23):5644-54. PubMed ID: 17956081
[TBL] [Abstract][Full Text] [Related]
15. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli.
Netzel TC; Jindani I; Hanson N; Turner BM; Smith L; Rand KH
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):345-8. PubMed ID: 17379469
[TBL] [Abstract][Full Text] [Related]
16. Functional analyses of AmpC beta-lactamase through differential stability.
Beadle BM; McGovern SL; Patera A; Shoichet BK
Protein Sci; 1999 Sep; 8(9):1816-24. PubMed ID: 10493583
[TBL] [Abstract][Full Text] [Related]
17. Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1.
Moloughney JG; D Thomas J; Toney JH
FEMS Microbiol Lett; 2005 Feb; 243(1):65-71. PubMed ID: 15668002
[TBL] [Abstract][Full Text] [Related]
18. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity.
Tan Q; Ogawa AM; Painter RE; Park YW; Young K; DiNinno FP
Bioorg Med Chem Lett; 2010 Apr; 20(8):2622-4. PubMed ID: 20299220
[TBL] [Abstract][Full Text] [Related]
19. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
